Osimertinib/Tagressa and fumetinib: Comparison of the efficacy of two EGFR inhibitors

Osimertinib and Furmonertinib are two targeted therapies mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). Both drugs are second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) and are widely used clinically for the treatment of patients with advanced or metastatic non-small cell lung cancer. Although their mechanisms of action are similar, by inhibiting the activity of mutant EGFR to prevent the growth of tumor cells, they differ in terms of efficacy, drug resistance, and side effects.

Osimertinib, as a third-generation EGFR inhibitor, is mainly used to treat patients with EGFR-positive non-small cell lung cancer with T790M mutation. This mutation is often the main cause of failure of first- and second-generation EGFR inhibitors. Osimertinib can not only effectively inhibit the activity of EGFR, but also penetrate the blood-brain barrier, and also has a good therapeutic effect on lung cancer patients with brain metastasis. Clinical studies have shown that osimertinib performs well in improving progression-free survival (PFS) and overall survival (OS) of patients, with mild side effects, mainly including rash and diarrhea, and less severe cardiac and pulmonary side effects.

Fumetinib is another new drug for patients with EGFR mutations. Fumetinib has shown good efficacy in the treatment of EGFR-mutant non-small cell lung cancer, especially in patients who are resistant to first- and second-generation EGFR inhibitors. Fumetinib shows strong efficacy by selectively inhibiting the mutant forms of EGFR, especially the T790M mutation and C797S mutation. Studies have shown that fumetinib can effectively prolong the progression-free survival of patients and provide new treatment options for some patients who are resistant to osimertinib.

Although the two drugs have similar mechanisms of action, they differ in their efficacy. As a widely used drug in clinical practice, osimertinib has been proven to have excellent efficacy in T790M mutation-positive patients and is highly recognized for its low frequency of side effects. Fumetinib is a new drug that has gained attention in recent years, especially in patients with some drug-resistant mutations, showing unique advantages. For those patients who fail to respond to osimertinib, fumetinib provides a new treatment option.

In summary, osimertinib and fumetinib each have their own advantages, and which drug to choose should be determined based on the patient's specific condition, mutation type, and drug resistance. ForOsimertinib is usually the first choice for patients who are T790M mutation-positive and have not yet developed resistance, while fumetinib can provide another treatment option for those patients who are resistant to osimertinib. In clinical application, doctors will formulate the most appropriate treatment plan based on the patient's individual situation and comprehensive consideration of the drug's efficacy, side effects, drug resistance and other factors.

Reference materials:https://go.drugbank.com/drugs/DB09330